Artificial Immune Modulation News Today

NexImmune (NASDAQ:NEXI – Get Free Report) and Spyre Therapeutics (NASDAQ:SYRE – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, profitability, analyst recommendations, earnings and risk. Insider and Institutional Ownership 9.9% of NexImmune shares […]

GAITHERSBURG, Md., Feb. 06, 2024 -- NexImmune, Inc. a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function...

NexImmune Announces Closing of $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules...

GAITHERSBURG, Md., Feb. 02, 2024 -- NexImmune, Inc. a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function...

GAITHERSBURG, Md., Feb. 02, 2024 -- NexImmune, Inc. a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function...

A JDRF funded grant is being used to explore the combination of NexImmune’s antigen specific nanoparticles and an anti-CD3 mAb for prevention and treatment of type 1 diabetes GAITHERSBURG, Md.,...

NexImmune, Inc. (NASDAQ:NEXI – Get Free Report) was the recipient of a significant growth in short interest in the month of September. As of September 30th, there was short interest totalling 134,900 shares, a growth of 21.3% from the September 15th total of 111,200 shares. Based on an average daily volume of 83,300 shares, the […]

Company retains core capabilities to continue to advance its nanoparticle injection platform and potential product candidates in oncology and autoimmune diseases GAITHERSBURG, Md., Aug. 31, 2023 ...

NexImmune, Inc. (NASDAQ:NEXI – Get Free Report) was the recipient of a significant drop in short interest during the month of July. As of July 15th, there was short interest totalling 286,700 shares, a drop of 19.3% from the June 30th total of 355,400 shares. Approximately 1.8% of the company’s shares are short sold. Based […]

NexImmune (NASDAQ:NEXI – Get Free Report) and Prothena (NASDAQ:PRTA – Get Free Report) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings. Risk and Volatility NexImmune has a beta of 2.2, meaning […]